SCHEDULE: Deep Track Capital Discloses 7.94% Stake in CorMedix

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have collectively reported beneficial ownership of 7.94% of CorMedix Inc.'s common stock as of March 31, 2026.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed a Schedule 13G, indicating their beneficial ownership of CorMedix Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially owned 6,274,076 shares of CorMedix Inc. common stock.
• This ownership stake represents 7.94% of the total outstanding common stock.
• The filing indicates shared voting and dispositive power for all reported shares among the reporting persons.
• David Kroin is identified as a control person for Deep Track Capital, LP.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a standard disclosure of beneficial ownership without additional commentary on the company's performance or future plans.

Positives

• Significant ownership stake of 7.94% in CorMedix Inc. by Deep Track Capital and associated entities.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Risks

• Potential for increased scrutiny from regulatory bodies due to the significant ownership stake.
• The filing does not provide specific reasons for the acquisition of shares, which could lead to speculation about the reporting persons' intentions.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding future performance or strategy.

Industry Context

StockSavvy.ai notes that significant stake disclosures like this often precede activist investor campaigns or strategic shifts within a company, particularly in the biotechnology sector where investor influence can be substantial.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership may influence market perception and trading activity.
• Management: May face increased scrutiny or engagement from Deep Track Capital regarding corporate strategy and governance.
• Creditors: No immediate impact indicated, but significant changes in company control could indirectly affect creditworthiness.

Next Steps

• Monitor future filings from Deep Track Capital for any changes in ownership or disclosed intentions.
• Observe CorMedix Inc.'s strategic responses or communications following this disclosure.

Key Dates

Keywords

CorMedix Inc., Schedule 13G, Deep Track Capital, Beneficial Ownership, Common Stock, SEC Filing, Investment, Biotechnology